Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Halomonas flagellata strain:EGI 63088

ABSTRACT: Halomonas flagellata strain:EGI 63088 Genome sequencing and assembly

PROVIDER: PRJNA809851 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Acidimicrobiia strain:EGI L10123 | isolate:EGI L10123

Project description:Acidimicrobiia strain:EGI L10123 | isolate:EGI L10123 Genome sequencing

| PRJNA1012832 | ENA

Demequina muriae strain:EGI L300058 | isolate:EGI L300058

Project description:Demequina muriae strain:EGI L300058 | isolate:EGI L300058 Genome sequencing and assembly

| PRJNA980646 | ENA

EGI-1 cell line treated with Saracatinib vs EGI-1 cell line untreated; EGI-1 xenograft treated with Saracatinib vs EGI-1 untreated

Project description:Biliary tract carcinoma (BTC) has a poor prognosis due to limited treatment options. There is therefore urgent need to identify new targets and to design innovative therapeutic approaches. Among potential candidate molecules, we evaluated the non-receptor tyrosine kinase Src, observing promising antitumor effects of its small molecule inhibitor Saracatinib in BTC preclinical models. The presence of an active Src protein was investigated by immunohistochemistry in 19 surgical samples from BTC patients. Upon Saracatinib treatment, the phosphorylation of Src and of its downstream transducers was evaluated in the BTC cell lines TFK-1, EGI-1, HuH28 and TGBC1-TKB. The effect of Saracatinib on proliferation and migration was analyzed in these same cell lines, and its antitumor activity was essayed in EGI-1 mouse xenografts. Saracatinib-modulated transcriptome was profiled in EGI-1 cells and in tumor samples of the xenograft model. Src was activated in about 80% of the human BTC samples. In cultured BTC cell lines, low-dose Saracatinib counteracted the activation of Src and of its downstream effectors, increased the fraction of cells in G0/G1 phase, and inhibited cell migration. At high concentrations (median dose from 2.26 to 6.99 µM), Saracatinib was also capable of inhibiting BTC cell proliferation. In vivo, Saracatinib treatment resulted in delayed tumor growth, associated with an impaired vascular network. We here provide a demonstration that the targeted inhibition of Src kinase by Saracatinib is of therapeutic benefit in preclinical models of BTC. We propose our results as a basis for the design of Saracatinib-based clinical applications. EGI-1 cell line treated with Saracatinib at the dose of 10 µM vs EGI-1 cell line untreated; EGI-1 xenograft treated with Saracatinib at the dose of 25 mg/Kg/die vs EGI-1 xenograft untreated Transcriptional alteration mediated by Saracatinib in vitro and in vivo

2012-08-02 | E-GEOD-36622 | biostudies-arrayexpress

Phytoactinopolyspora endophytica strain:EGI 60009

Project description:Phytoactinopolyspora endophytica strain:EGI 60009 Genome sequencing and assembly

| PRJNA511631 | ENA

Chelativorans salis strain:EGI FJ00035

Project description:Chelativorans salis strain:EGI FJ00035 Genome sequencing and assembly

| PRJNA880480 | ENA

Ornithinimicrobium sediminis strain:EGI L100131

Project description:Ornithinimicrobium sediminis strain:EGI L100131 Genome sequencing and assembly

| PRJNA789434 | ENA

Paracoccus salsus strain:EGI L200073

Project description:Paracoccus salsus strain:EGI L200073 Genome sequencing and assembly

| PRJNA797938 | ENA

Rhabdothermincola salaria strain:EGI L10124

Project description:Rhabdothermincola salaria strain:EGI L10124 Genome sequencing and assembly

| PRJNA788389 | ENA

Labedella endophytica strain:EGI 6500705

Project description:Labedella endophytica strain:EGI 6500705 Genome sequencing and assembly

| PRJNA511610 | ENA

Ornithinicoccus halotolerans strain:EGI 80423

Project description:Ornithinicoccus halotolerans strain:EGI 80423 Genome sequencing and assembly

| PRJNA579871 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data